Noemi Reguart-Aransay - Publications

Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: May 26, 2026

Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer.

Journal: The oncologist

Published: June 13, 2024

A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 15, 2016

Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.

Journal: Clinical chemistry

Published: August 12, 2016

miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancers.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: May 15, 2015

Matrix stiffening and β1 integrin drive subtype-specific fibroblast accumulation in lung cancer.

Journal: Molecular cancer research : MCR

Published: October 05, 2014

Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.

Journal: Cancer treatment reviews

Published: August 25, 2014

Beyond EGFR TKI in EGFR-mutant non-small cell lung cancer patients: main challenges still to be overcome.

Journal: Cancer treatment reviews

Published: February 21, 2014

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 28, 2013